We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Combating Infectious Diseases Key Focus of AACC

By LabMedica International staff writers
Posted on 03 Aug 2017
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation, with the focus being largely on speed and effectiveness in infectious disease detection.

According to Kalorama Information, (New York, NY, USA), an independent medical market research firm, diseases caused by infection are among the largest and most competitive markets for in vitro diagnostics (IVD) instruments, kits and reagents. The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, saw important product announcements for early and accurate detection for the treatment of infectious diseases.

Some of the product announcements at the event included a new method for detecting 5 gram-negative bacteria using genoproteomic peptide marker analysis on a combined MS/LC system. Additionally, Ortho Clinical Diagnostics showcased its Vitros Immunodiagnostic Products human immunodeficiency virus (HIV) combo assay for use on the Vitros 3600 immunodiagnostic system. A fourth-generation HIV assay, the Vitros HIV combo is designed to detect acute HIV-1 infection earlier than previous generations of HIV assays.

Further, Aalto Bio Reagents, a developer and provider of raw materials to the in- vitro diagnostics industry and to research laboratories globally, announced their first-to-market recombinant Yellow Fever Virus (YFV) protein. Also, Seegene Inc. announced a Random Access System, which can provide order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.

Related Links:
Kalorama Information

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Steam Sterilizer
Hi Vac II Line
New
Rapid Sepsis Test
SeptiCyte RAPID

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG